GlassScriptPhysician profile
Christopher H Cantrill
NPI 1568642296
$73,436.85
in general payments reported to CMS, 2019-2025
23 companies · $437 in 2025
The $437 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $24K · 2021: $9,706 · 2022: $7,179 · 2023: $2,215 · 2024: $4,592 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,127 · Food and Beverage: $1,766 · Travel and Lodging: $1,316 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,127.00 |
| Food and Beverage | $1,765.79 |
| Travel and Lodging | $1,316.29 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $65,794.18 | 2019-2024 | Tactra, Rezum Generator, Lithovue Empower |
| Procept Biorobotics Corporation | $6,120.23 | 2020-2025 | Aquabeam System, Aquabeam Robotic System |
| Olympus America INC. | $240.37 | 2023-2025 | Itind System |
| Medtronic, INC. | $187.77 | 2024 | Interstim |
| Janssen Biotech, INC. | $178.63 | 2019-2023 | Erleada |
| Ferring Pharmaceuticals INC. | $124.66 | 2019-2025 | Adstiladrin |
| Angiodynamics, INC. | $119.33 | 2024 | Nanoknife |
| Coloplast Corp | $109.83 | 2024 | |
| Sumitomo Pharma America, INC. | $106.52 | 2023-2025 | Orgovyx, Gemtesa |
| Blue Earth Diagnostics | $92.10 | 2019-2022 | |
| Astellas Pharma US INC | $87.17 | 2019 | |
| Progenics Pharmaceuticals, INC. | $64.95 | 2023 | Pylarify |
| Cook Medical LLC | $58.74 | 2025 | Litho 150 |
| Photocure INC | $37.69 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $34.71 | 2022 | |
| Teleflex LLC | $18.42 | 2022 | |
| Antares Pharma, INC. | $13.69 | 2019 | |
| Genzyme Corporation | $12.80 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cantrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.